{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:24:13Z","timestamp":1790162653455,"version":"4.1.0"},"reference-count":184,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T00:00:00Z","timestamp":1671667200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biology"],"abstract":"<jats:p>Hepatitis C virus (HCV) is a significant cause of chronic liver diseases worldwide and is associated with negative consequences, including cirrhosis, hepatic decompensation, hepatocellular carcinoma, and increased risk of mortality. In addition to liver-related morbidities, HCV is also associated with several extrahepatic manifestations, including mixed cryoglobulinemia, diabetes mellitus, cardiocerebrovascular disease, lymphoma, and autoimmune diseases. These non-liver-related complications of HCV increase the complexity of this disease and can contribute to the economic burden, morbidity, quality of life, and mortality throughout the world. Therefore, understanding how this virus can contribute to each extrahepatic manifestation is worth investigating. Currently, the advancement of HCV treatment with the advent of direct-acting anti-viral agents (DAAs) has led to a high cure rate as a result of sustained virologic response and tremendously reduced the burden of extrahepatic complications. However, HCV-associated extrahepatic manifestations remain a relevant concern, and this review aims to give an updated highlight of the prevalence, risk factors, associated burdens, and treatment options for these conditions.<\/jats:p>","DOI":"10.3390\/biology12010023","type":"journal-article","created":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T02:36:46Z","timestamp":1671763006000},"page":"23","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Burden, Outcome, and Comorbidities of Extrahepatic Manifestations in Hepatitis C Virus Infection"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4117-4272","authenticated-orcid":false,"given":"Busara","family":"Songtanin","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2781-4816","authenticated-orcid":false,"given":"Kenneth","family":"Nugent","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,12,22]]},"reference":[{"key":"ref_1","unstructured":"(2017). Global Hepatitis Report 2017, World Health Organization."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/hep.30297","article-title":"Estimating Prevalence of Hepatitis C Virus Infection in the United States, 2013\u20132016","volume":"69","author":"Hofmeister","year":"2018","journal-title":"Hepatology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/ajt.15674","article-title":"OPTN\/SRTR 2018 Annual Data Report: Liver","volume":"20","author":"Kwong","year":"2020","journal-title":"Am. J. Transpl."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/S1473-3099(12)70010-5","article-title":"Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: Towards a vaccine","volume":"12","author":"Grebely","year":"2012","journal-title":"Lancet Infect. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/nrgastro.2016.176","article-title":"Global epidemiology and burden of HCV infection and HCV-related disease","volume":"14","author":"Thrift","year":"2017","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1053\/j.gastro.2019.06.026","article-title":"Trends in Mortality From Extrahepatic Complications in Patients With Chronic Liver Disease, From 2007 Through 2017","volume":"157","author":"Kim","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/infdis\/jis385","article-title":"Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: A community-based long-term prospective study","volume":"206","author":"Lee","year":"2012","journal-title":"J. Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1002\/1529-0131(199910)42:10<2204::AID-ANR24>3.0.CO;2-D","article-title":"Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment Virus C","volume":"42","author":"Cacoub","year":"1999","journal-title":"Arthritis Rheum."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1053\/j.gastro.2016.02.039","article-title":"Extrahepatic Manifestations of Hepatitis C: A Meta-analysis of Prevalence, Quality of Life, and Economic Burden","volume":"150","author":"Younossi","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.3760\/cma.j.issn.0366-6999.20132988","article-title":"Extrahepatic manifestations of chronic hepatitis C virus infection: 297 cases from a tertiary medical center in Beijing, China","volume":"127","author":"Cheng","year":"2014","journal-title":"Chin. Med. J."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S0002-9440(10)63673-5","article-title":"Dynamics of hepatitis C virus replication in human liver","volume":"163","author":"Chang","year":"2003","journal-title":"Am. J. Pathol."},{"key":"ref_12","first-page":"433","article-title":"Comparison of hepatitis C viral loads in patients with or without coinfection with different genotypes","volume":"11","author":"Schijman","year":"2004","journal-title":"Clin. Diagn Lab. Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJMra2033539","article-title":"Extrahepatic Manifestations of Chronic HCV Infection","volume":"384","author":"Cacoub","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_14","unstructured":"AASLD\/IDSA HCV Guidance Panel (2022, September 20). Recommendations for Testing, Managing, and Treating Hepatitis C. Updated August 27, 2020. Available online: http:\/\/hcvguidelines.org\/."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.jhep.2019.07.021","article-title":"Sustained virological response from interferon-based hepatitis C regimens is associated with reduced risk of extrahepatic manifestations","volume":"71","author":"Rossi","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/hep4.1049","article-title":"Prevalence and economic burden of extrahepatic manifestations of hepatitis C virus are underestimated but can be improved with therapy","volume":"1","author":"Reau","year":"2017","journal-title":"Hepatol. Commun."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/00000441-200303000-00006","article-title":"Extrahepatic Manifestations of Hepatitis C Infection","volume":"325","author":"Mayo","year":"2003","journal-title":"Am. J. Med. Sci."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/apt.15131","article-title":"Systematic review with meta-analysis: Extrahepatic manifestations in chronic hepatitis C virus-infected patients in East Asia","volume":"49","author":"Younossi","year":"2019","journal-title":"Aliment. Pharm."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/S2468-1253(19)30227-4","article-title":"Global burden of atherosclerotic cardiovascular disease in people with hepatitis C virus infection: A systematic review, meta-analysis, and modelling study","volume":"4","author":"Lee","year":"2019","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1053\/j.gastro.2015.09.007","article-title":"Hepatitis C Virus Infection Is Associated With Increased Cardiovascular Mortality: A Meta-Analysis of Observational Studies","volume":"150","author":"Petta","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/hep.29505","article-title":"Chronic hepatitis C virus (HCV) increases the risk of chronic kidney disease (CKD) while effective HCV treatment decreases the incidence of CKD","volume":"67","author":"Park","year":"2018","journal-title":"Hepatology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.cgh.2008.02.011","article-title":"Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the International Lymphoma Epidemiology Consortium","volume":"6","author":"Benavente","year":"2008","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4254\/wjh.v8.i2.107","article-title":"Hepatitis C virus and non-Hodgkin\u2019s lymphomas: Meta-analysis of epidemiology data and therapy options","volume":"8","author":"Pozzato","year":"2016","journal-title":"World J. Hepatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S0168-8278(03)00346-5","article-title":"Prevalence of hepatitis C virus infection in porphyria cutanea tarda: Systematic review and meta-analysis","volume":"39","author":"Gisbert","year":"2003","journal-title":"J. Hepatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/adj.12382","article-title":"Hepatitis C virus infections in oral lichen planus: A systematic review and meta-analysis","volume":"61","author":"Alaizari","year":"2016","journal-title":"Aust Dent. J."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Yeh, C.C., Wang, W.C., Wu, C.S., Sung, F.C., Su, C.T., Shieh, Y.H., Chang, S.N., and Su, F.H. (2016). Association of Sjogrens Syndrome in Patients with Chronic Hepatitis Virus Infection: A Population-Based Analysis. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0164911"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"227","DOI":"10.15403\/jgld.2014.1121.252.chc","article-title":"Thyroid Disturbance in Patients with Chronic Hepatitis C Infection: A Systematic Review and Meta-analysis","volume":"25","author":"Shen","year":"2016","journal-title":"J. Gastrointestin Liver Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3389\/fendo.2015.00134","article-title":"Diabetes and Hepatitis C: A Two-Way Association","volume":"6","author":"Hammerstad","year":"2015","journal-title":"Front. Endocrinol."},{"key":"ref_29","first-page":"1140","article-title":"Glucose Abnormalities in Patients with Hepatitis C Virus Infection","volume":"29","author":"Lecube","year":"2006","journal-title":"Epidemiol. Pathog."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1111\/j.1572-0241.2005.41403.x","article-title":"Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy","volume":"100","author":"Sabin","year":"2005","journal-title":"Am. J. Gastroenterol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1053\/j.gastro.2003.10.065","article-title":"Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma","volume":"126","author":"Tran","year":"2004","journal-title":"Gastroenterology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jhep.2018.02.015","article-title":"Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis","volume":"69","author":"Petta","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1097\/MAJ.0b013e3182a5587d","article-title":"The impact of hepatitis C infection on ischemic heart disease via ischemic electrocardiogram","volume":"347","author":"Lin","year":"2014","journal-title":"Am. J. Med. Sci"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1053\/j.gastro.2019.02.009","article-title":"Hepatitis C Virus Infection, a New Modifiable Cardiovascular Risk Factor","volume":"156","author":"Cacoub","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.semarthrit.2003.10.001","article-title":"Mixed cryoglobulinemia: Demographic, clinical, and serologic features and survival in 231 patients","volume":"33","author":"Ferri","year":"2004","journal-title":"Semin Arthritis Rheum."},{"key":"ref_36","first-page":"1661","article-title":"Most patients with HCV-associated lymphoma present with mild liver disease: A call to revise antiviral treatment prioritization","volume":"35","author":"Torres","year":"2015","journal-title":"Liver Int. Off. J. Int. Assoc. Study Liver"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.18632\/oncotarget.23138","article-title":"Hepatitis C virus infection is an independent prognostic factor in follicular lymphoma","volume":"9","author":"Shimono","year":"2018","journal-title":"Oncotarget"},{"key":"ref_38","first-page":"2245","article-title":"Prevalence and characteristics of Sjogren\u2019s syndrome or Sicca syndrome in chronic hepatitis C virus infection: A prospective study","volume":"28","author":"Riche","year":"2001","journal-title":"J. Rheumatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1002\/art.10221","article-title":"Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjogren\u2019s syndrome","volume":"46","author":"Ioannidis","year":"2002","journal-title":"Arthritis Rheum."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1002\/1529-0131(199908)42:8<1765::AID-ANR28>3.0.CO;2-V","article-title":"Malignant lymphoma in primary Sjogren\u2019s syndrome: A multicenter, retrospective, clinical study by the European Concerted Action on Sjogren\u2019s Syndrome","volume":"42","author":"Voulgarelis","year":"1999","journal-title":"Arthritis Rheum."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1093\/rheumatology\/keh668","article-title":"Rheumatological manifestations of hepatitis C: Incidence in a rheumatology and non-rheumatology setting and the effect of methotrexate and interferon","volume":"44","author":"Nissen","year":"2005","journal-title":"Rheumatology"},{"key":"ref_42","first-page":"183","article-title":"Prevalence of HCV antibodies in autoimmune thyroid disease","volume":"10","author":"Testa","year":"2006","journal-title":"Eur Rev. Med. Pharm. Sci."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3892\/etm.2014.1709","article-title":"Possible factors affecting thyroid dysfunction in hepatitis C virus-infected untreated patients","volume":"8","author":"Mao","year":"2014","journal-title":"Exp. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.3748\/wjg.v16.i16.1943","article-title":"Importance of hepatitis C virus-associated insulin resistance: Therapeutic strategies for insulin sensitization","volume":"16","author":"Kawaguchi","year":"2010","journal-title":"World J. Gastroenterol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1053\/j.gastro.2007.11.010","article-title":"Insulin resistance in chronic hepatitis C: Association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis","volume":"134","author":"Moucari","year":"2008","journal-title":"Gastroenterology"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.3748\/wjg.v23.i9.1697","article-title":"Diabetes mellitus, insulin resistance and hepatitis C virus infection: A contemporary review","volume":"23","author":"Desbois","year":"2017","journal-title":"World J. Gastroenterol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1053\/jhep.2003.50291","article-title":"Hepatitis C virus infection and incident type 2 diabetes","volume":"38","author":"Mehta","year":"2003","journal-title":"Hepatology"},{"key":"ref_48","first-page":"2548","article-title":"Hepatitis C Virus Infection","volume":"28","author":"Antonelli","year":"2005","journal-title":"Evid. Assoc. Type 2 Diabetes"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.jhep.2008.08.006","article-title":"Hepatitis C infection and risk of diabetes: A systematic review and meta-analysis","volume":"49","author":"White","year":"2008","journal-title":"J. Hepatol."},{"key":"ref_50","first-page":"544","article-title":"High prevalence of diabetes mellitus in patients with chronic hepatitis C. A case-control study","volume":"20","author":"Grimbert","year":"1996","journal-title":"Gastroenterol. Clin. Et Biol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"52","DOI":"10.4239\/wjd.v5.i1.52","article-title":"Hepatitis C virus infection and insulin resistance","volume":"5","author":"Bose","year":"2014","journal-title":"World J. Diabetes"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"5014","DOI":"10.3748\/wjg.15.5014","article-title":"Steatosis and insulin resistance in hepatitis C: A way out for the virus?","volume":"15","year":"2009","journal-title":"World J. Gastroenterol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3748\/wjg.15.280","article-title":"Liver cirrhosis and diabetes: Risk factors, pathophysiology, clinical implications and management","volume":"15","year":"2009","journal-title":"World J. Gastroenterol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"586","DOI":"10.4239\/wjd.v5.i5.586","article-title":"Hepatitis C virus infection and type 1 and type 2 diabetes mellitus","volume":"5","author":"Antonelli","year":"2014","journal-title":"World J. Diabetes"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jhep.2022.01.029","article-title":"Metabolic dysfunction and cancer in HCV: Shared pathways and mutual interactions","volume":"77","author":"Leslie","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.3748\/wjg.v20.i11.2888","article-title":"Interaction between hepatitis C virus and metabolic factors","volume":"20","author":"Kawaguchi","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.3748\/wjg.v17.i36.4055","article-title":"Pathophysiology of insulin resistance and steatosis in patients with chronic viral hepatitis","volume":"17","author":"Basaranoglu","year":"2011","journal-title":"World J. Gastroenterol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/j.1572-0241.2006.01038.x","article-title":"Clearance of HCV improves insulin resistance, beta-cell function, and hepatic expression of insulin receptor substrate 1 and 2","volume":"102","author":"Kawaguchi","year":"2007","journal-title":"Am. J. Gastroenterol."},{"key":"ref_59","first-page":"4974","article-title":"Meta-analysis: Impact of sustained virological response on insulin resistance during hepatitis C therapy","volume":"9","author":"Gao","year":"2016","journal-title":"Int. J. Clin. Exp. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.3748\/wjg.v24.i11.1269","article-title":"Fatty liver in hepatitis C patients post-sustained virological response with direct-acting antivirals","volume":"24","author":"Noureddin","year":"2018","journal-title":"World J. Gastroenterol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1136\/gut.2002.009936","article-title":"Effect of antiviral treatment on evolution of liver steatosis in patients with chronic hepatitis C: Indirect evidence of a role of hepatitis C virus genotype 3 in steatosis","volume":"53","author":"Lonjon","year":"2004","journal-title":"Gut"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"14506","DOI":"10.1038\/s41598-021-93881-7","article-title":"Comparison of liver biopsies before and after direct-acting antiviral therapy for hepatitis C and correlation with clinical outcome","volume":"11","author":"Saldarriaga","year":"2021","journal-title":"Sci Rep."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1016\/j.jhep.2014.08.003","article-title":"Facts and fictions of HCV and comorbidities: Steatosis, diabetes mellitus, and cardiovascular diseases","volume":"61","author":"Negro","year":"2014","journal-title":"J. Hepatol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1136\/gut.2004.052167","article-title":"Diabetes increases the risk of hepatocellular carcinoma in the United States: A population based case control study","volume":"54","author":"Davila","year":"2005","journal-title":"Gut"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.2337\/dc06-0456","article-title":"Sustained virological response correlates with reduction in the incidence of glucose abnormalities in patients with chronic hepatitis C virus infection","volume":"29","author":"Simo","year":"2006","journal-title":"Diabetes Care"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1111\/jgh.14067","article-title":"Hepatitis C virus clearance by direct-acting antiviral treatments and impact on insulin resistance in chronic hepatitis C patients","volume":"33","author":"Adinolfi","year":"2018","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.2337\/dc17-0485","article-title":"Improvement in Glycemic Control of Type 2 Diabetes After Successful Treatment of Hepatitis C Virus","volume":"40","author":"Hum","year":"2017","journal-title":"Diabetes Care"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/jvh.12143","article-title":"Eradicating hepatitis C virus ameliorates insulin resistance without change in adipose depots","volume":"21","author":"Milner","year":"2014","journal-title":"J. Viral Hepat."},{"key":"ref_69","first-page":"1153","article-title":"Hepatitis C Virus (HCV) Treatment With Directly Acting Agents Reduces the Risk of Incident Diabetes: Results From Electronically Retrieved Cohort of HCV Infected Veterans (ERCHIVES)","volume":"70","author":"Butt","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/apt.15102","article-title":"Sustained virological response to hepatitis C treatment decreases the incidence of complications associated with type 2 diabetes","volume":"49","author":"Li","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_71","unstructured":"World Health Organization (2022, September 01). Top 10 Causes of Death, Available online: http:\/\/origin.who.int\/gho\/mortality_burden_disease\/causes_death\/top_10\/en\/."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/jgh.12313","article-title":"Chronic hepatitis C infection is associated with insulin resistance and lipid profiles","volume":"30","author":"Dai","year":"2015","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/j.1365-2893.2005.00655.x","article-title":"Serum lipid pattern in chronic hepatitis C: Histological and virological correlations","volume":"13","author":"Siagris","year":"2006","journal-title":"J. Viral Hepat."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1161\/STROKEAHA.110.598136","article-title":"Hepatitis C virus infection and increased risk of cerebrovascular disease","volume":"41","author":"Lee","year":"2010","journal-title":"Stroke"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/apt.12391","article-title":"Interferon-based therapy reduces risk of stroke in chronic hepatitis C patients: A population-based cohort study in Taiwan","volume":"38","author":"Hsu","year":"2013","journal-title":"Aliment. Pharm."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.amjcard.2015.06.035","article-title":"Comparison of Angiographic Burden of Coronary Artery Disease in Patients With Versus Without Hepatitis C Infection","volume":"116","author":"Pothineni","year":"2015","journal-title":"Am. J. Cardiol."},{"key":"ref_77","first-page":"1001","article-title":"Chronic viral hepatitis: A prospective factor against atherosclerosis. A study with echo-color Doppler of the carotid and femoral arteries and the abdominal aorta","volume":"26","author":"Bilora","year":"2002","journal-title":"Gastroenterol. Clin. Et Biol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1002\/hep.23219","article-title":"Hepatitis C virus infection and its clearance alter circulating lipids: Implications for long-term follow-up","volume":"50","author":"Corey","year":"2009","journal-title":"Hepatology"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1053\/j.gastro.2016.09.009","article-title":"Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications","volume":"152","author":"Nahon","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/hep.23031","article-title":"Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C","volume":"50","author":"Vanni","year":"2009","journal-title":"Hepatology"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1016\/S1590-8658(07)80012-0","article-title":"HCV infection facilitates asymptomatic carotid atherosclerosis: Preliminary report of HCV RNA localization in human carotid plaques","volume":"39","author":"Boddi","year":"2007","journal-title":"Dig. Liver Dis."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.cld.2017.03.003","article-title":"Cardiovascular Manifestations of Hepatitis C Virus","volume":"21","author":"Goossens","year":"2017","journal-title":"Clin. Liver Dis."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.cardfail.2008.12.003","article-title":"Association of hepatitis C virus seropositivity with inflammatory markers and heart failure in persons with coronary heart disease: Data from the Heart and Soul study","volume":"15","author":"Tsui","year":"2009","journal-title":"J. Card Fail."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/cid\/cix359","article-title":"Risk of Acute Myocardial Infarction Among Hepatitis C Virus (HCV)-Positive and HCV-Negative Men at Various Lipid Levels: Results From ERCHIVES","volume":"65","author":"Butt","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jhep.2012.07.045","article-title":"Myocardial injury in patients with chronic hepatitis C infection","volume":"58","author":"Maruyama","year":"2013","journal-title":"J. Hepatol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1053\/j.gastro.2018.11.022","article-title":"Direct-Acting Antiviral Therapy for HCV Infection Is Associated With a Reduced Risk of Cardiovascular Disease Events","volume":"156","author":"Butt","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1136\/gutjnl-2017-313983","article-title":"The effect of sustained virological response on the risk of extrahepatic manifestations of hepatitis C virus infection","volume":"67","author":"Mahale","year":"2018","journal-title":"Gut"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jhep.2013.03.018","article-title":"Hepatitis C-associated B-cell non-Hodgkin lymphomas. Epidemiology, molecular signature and clinical management","volume":"59","author":"Arcaini","year":"2013","journal-title":"J. Hepatol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1089\/jir.2009.0047","article-title":"Possible recruitment of peripheral blood CXCR3+ CD27+ CD19+ B cells to the liver of chronic hepatitis C patients","volume":"30","author":"Mizuochi","year":"2010","journal-title":"J. Interferon Cytokine Res. Off. J. Int. Soc. Interferon Cytokine Res."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Mazzaro, C., Maso, L.D., Mauro, E., Gattei, V., Ghersetti, M., Bulian, P., Moratelli, G., Grassi, G., Zorat, F., and Pozzato, G. (2018). Survival and Prognostic Factors in Mixed Cryoglobulinemia: Data from 246 Cases. Diseases, 6.","DOI":"10.3390\/diseases6020035"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1046\/j.1365-2893.1998.00097.x","article-title":"Systemic manifestations and liver disease in patients with chronic hepatitis C and type II or III mixed cryoglobulinaemia","volume":"5","author":"Donada","year":"1998","journal-title":"J. Viral Hepat."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1053\/j.ajkd.2012.08.040","article-title":"Hepatitis C virus infection, mixed cryoglobulinemia, and kidney disease","volume":"61","author":"Fabrizi","year":"2013","journal-title":"Am. J. Kidney Dis. Off. J. Natl. Kidney Found."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1038\/ki.1995.78","article-title":"Long-term predictors of survival in essential mixed cryoglobulinemic glomerulonephritis","volume":"47","author":"Tarantino","year":"1995","journal-title":"Kidney Int."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"7544","DOI":"10.3748\/wjg.v20.i24.7544","article-title":"Hepatitis C virus associated glomerulopathies","volume":"20","author":"Ozkok","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1093\/annonc\/mdx635","article-title":"From hepatitis C virus infection to B-cell lymphoma","volume":"29","author":"Bachy","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jare.2016.07.004","article-title":"Hepatitis C and kidney disease: A narrative review","volume":"8","author":"Barsoum","year":"2017","journal-title":"J. Adv. Res."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1093\/rheumatology\/kel177","article-title":"Hepatitis C virus-associated B-cell proliferation--the role of serum B lymphocyte stimulator (BLyS\/BAFF)","volume":"46","author":"Limal","year":"2007","journal-title":"Rheumatology"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1002\/art.30274","article-title":"Genetic determinants in hepatitis C virus-associated mixed cryoglobulinemia: Role of polymorphic variants of BAFF promoter and Fc\u03b3 receptors","volume":"63","author":"Gragnani","year":"2011","journal-title":"Arthritis Rheum."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1002\/art.30319","article-title":"Prognostic factors in patients with hepatitis C virus infection and systemic vasculitis","volume":"63","author":"Terrier","year":"2011","journal-title":"Arthritis Rheum."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1182\/blood.V81.5.1132.1132","article-title":"Interferon-alpha in mixed cryoglobulinemia patients: A randomized, crossover-controlled trial","volume":"81","author":"Ferri","year":"1993","journal-title":"Blood"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1056\/NEJM199403173301104","article-title":"Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus","volume":"330","author":"Misiani","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1056\/NEJMra1208642","article-title":"Therapy for hepatitis C virus-related cryoglobulinemic vasculitis","volume":"369","author":"Dammacco","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jhep.2014.08.015","article-title":"PegIFNalpha\/ribavirin\/protease inhibitor combination in severe hepatitis C virus-associated mixed cryoglobulinemia vasculitis","volume":"62","author":"Saadoun","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1038\/ajg.2017.49","article-title":"Efficacy and Safety of Direct Acting Antivirals for the Treatment of Mixed Cryoglobulinemia","volume":"112","author":"Emery","year":"2017","journal-title":"Am. J. Gastroenterol."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"(2020). EASL recommendations on treatment of hepatitis C: Final update of the series(\u2606). J. Hepatol., 73, 1170\u20131218.","DOI":"10.1016\/j.jhep.2020.08.018"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1111\/apt.15240","article-title":"The effects of sustained virological response to direct-acting anti-viral therapy on the risk of extrahepatic manifestations of hepatitis C infection","volume":"49","author":"Christie","year":"2019","journal-title":"Aliment. Pharm."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1001\/archinte.165.1.101","article-title":"Incidence and Characteristics of Non-Hodgkin Lymphomas in a Multicenter Case File of Patients With Hepatitis C Virus\u2013Related Symptomatic Mixed Cryoglobulinemias","volume":"165","author":"Monti","year":"2005","journal-title":"Arch. Intern. Med."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/00042737-200402000-00003","article-title":"The prevalence of hepatitis C virus infection in patients with non-Hodgkin\u2019s lymphoma","volume":"16","author":"Gisbert","year":"2004","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"8835","DOI":"10.1128\/JVI.78.16.8835-8843.2004","article-title":"Hepatitis C virus infection activates the immunologic (type II) isoform of nitric oxide synthase and thereby enhances DNA damage and mutations of cellular genes","volume":"78","author":"Machida","year":"2004","journal-title":"J. Virol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/jvh.12518","article-title":"The anti-lymphoma activity of antiviral therapy in HCV-associated B-cell non-Hodgkin lymphomas: A meta-analysis","volume":"23","author":"Arcaini","year":"2016","journal-title":"J. Viral Hepat."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/hep.29364","article-title":"Efficacy and safety of new direct antiviral agents in hepatitis C virus\u2013infected patients with diffuse large B-cell non-Hodgkin\u2019s lymphoma","volume":"67","author":"Persico","year":"2018","journal-title":"Hepatology"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1007\/s10620-015-3801-y","article-title":"Hepatitis C Virus Infection Increases the Risk of Developing Chronic Kidney Disease: A Systematic Review and Meta-Analysis","volume":"60","author":"Fabrizi","year":"2015","journal-title":"Dig. Dis. Sci."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.kisu.2018.06.001","article-title":"KDIGO 2018 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease","volume":"8","year":"2018","journal-title":"Kidney Int. Suppl."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1681\/ASN.V9122244","article-title":"Hepatitis C viral infection is associated with fibrillary glomerulonephritis and immunotactoid glomerulopathy","volume":"9","author":"Markowitz","year":"1998","journal-title":"J. Am. Soc. Nephrol. JASN"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"e535","DOI":"10.1016\/j.ijid.2013.01.017","article-title":"Detection of viral antigens in renal tissue of glomerulonephritis patients without serological evidence of hepatitis B virus and hepatitis C virus infection","volume":"17","author":"Kong","year":"2013","journal-title":"Int J. Infect. Dis."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.virol.2005.01.013","article-title":"HCV associated glomerulopathy in Egyptian patients: Clinicopathological analysis","volume":"334","author":"Sabry","year":"2005","journal-title":"Virology"},{"key":"ref_117","first-page":"813","article-title":"Therapy of hepatitis C virus-associated glomerulonephritis: Current approaches","volume":"21","author":"Fabrizi","year":"2008","journal-title":"J. Nephrol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3851\/IMP3247","article-title":"Expert Opinion on the Management of Renal Manifestations of Chronic HCV Infection","volume":"23","author":"Fabrizi","year":"2018","journal-title":"Antivir. Ther."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2215\/CJN.03710708","article-title":"Hepatitis C Infection and Chronic Renal Diseases","volume":"4","author":"Perico","year":"2009","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"370","DOI":"10.2353\/ajpath.2006.050491","article-title":"Novel role of toll-like receptor 3 in hepatitis C-associated glomerulonephritis","volume":"168","author":"Schmid","year":"2006","journal-title":"Am. J. Pathol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0272-6386(96)90156-0","article-title":"High binding of immunoglobulin M kappa rheumatoid factor from type II cryoglobulins to cellular fibronectin: A mechanism for induction of in situ immune complex glomerulonephritis?","volume":"27","author":"Fornasieri","year":"1996","journal-title":"Am. J. Kidney Dis. Off. J. Natl. Kidney Found."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1093\/ndt\/17.2.239","article-title":"A comprehensive study of the association between hepatitis C virus and glomerulopathy","volume":"17","author":"Sabry","year":"2002","journal-title":"Nephrol. Dial. Transpl."},{"key":"ref_123","first-page":"829A","article-title":"Receiving directly acting antivirals (DAAs) for hepatitis C improves renal function in patients with CKD regardless of SVR","volume":"66","author":"Khan","year":"2017","journal-title":"Hepatology"},{"key":"ref_124","first-page":"519A","article-title":"Risk of end stage renal disease in hepatitis C patients following completion of direct-acting antiviral therapy: A retrospective cohort study","volume":"66","author":"Singer","year":"2017","journal-title":"Hepatology"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.4254\/wjh.v7.i27.2740","article-title":"Cutaneous manifestations of hepatitis C in the era of new antiviral agents","volume":"7","author":"Garcovich","year":"2015","journal-title":"World J. Hepatol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.cld.2004.07.001","article-title":"Hepatic porphyrias: Diagnosis and management","volume":"8","author":"Chemmanur","year":"2004","journal-title":"Clin. Liver Dis."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1172\/JCI108560","article-title":"An inherited enzymatic defect in porphyria cutanea tarda: Decreased uroporphyrinogen decarboxylase activity","volume":"58","author":"Kushner","year":"1976","journal-title":"J. Clin. Invest."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0190-9622(99)70402-0","article-title":"Porphyria cutanea tarda and hepatitis C virus: A case-control study and meta-analysis of the literature","volume":"41","author":"Chuang","year":"1999","journal-title":"J. Am. Acad Derm."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1002\/hep.510270627","article-title":"Porphyria cutanea tarda, hepatitis C, and HFE gene mutations in North America","volume":"27","author":"Bonkovsky","year":"1998","journal-title":"Hepatology"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.ymgme.2019.05.003","article-title":"Association between hepatitis C virus and porphyria cutanea tarda","volume":"128","year":"2019","journal-title":"Mol. Genet. Metab"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.cgh.2009.11.017","article-title":"Associations among behavior-related susceptibility factors in porphyria cutanea tarda","volume":"8","author":"Jalil","year":"2010","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/hep.510270128","article-title":"High prevalence of the His63Asp HFE mutation in Italian patients with porphyria cutanea tarda","volume":"27","author":"Sampietro","year":"1998","journal-title":"Hepatology"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1111\/apt.15703","article-title":"Resolution of subclinical porphyria cutanea tarda after hepatitis C eradication with direct-acting anti-virals","volume":"51","author":"Sastre","year":"2020","journal-title":"Aliment. Pharm."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.amjms.2017.03.007","article-title":"Hepatitis C Treatment in Patients With Porphyria Cutanea Tarda","volume":"353","author":"Singal","year":"2017","journal-title":"Am. J. Med. Sci"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s10620-007-9945-7","article-title":"Phlebotomy improves therapeutic response to interferon in patients with chronic hepatitis C: A meta-analysis of six prospective randomized controlled trials","volume":"53","author":"Desai","year":"2008","journal-title":"Dig. Dis. Sci"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.gastrohep.2021.09.001","article-title":"Evolution of HCV associated porphyria cutanea tarda after HCV sustained virologic response by direct acting antivirals","volume":"45","year":"2022","journal-title":"Gastroenterol. \u00cdA Y Hepatol. \u00cdA"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"737813","DOI":"10.3389\/fmed.2021.737813","article-title":"Lichen Planus","volume":"8","author":"Boch","year":"2021","journal-title":"Front. Med. (Lausanne)"},{"key":"ref_138","first-page":"519","article-title":"Oral lichen planus: A review","volume":"58","author":"Carrozzo","year":"2009","journal-title":"Minerva Stomatol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/j.1601-0825.2010.01670.x","article-title":"Hepatitis C virus infection and lichen planus: A systematic review with meta-analysis","volume":"16","author":"Lodi","year":"2010","journal-title":"Oral Dis."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00784-015-1602-5","article-title":"No association of oral lichen planus and hepatitis C virus infection in central Germany","volume":"20","author":"Remmerbach","year":"2016","journal-title":"Clin. Oral. Investig."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/j.1600-0714.2005.00303.x","article-title":"Hepatitis C virus-associated oral lichen planus: Is the geographical heterogeneity related to HLA-DR6?","volume":"34","author":"Carrozzo","year":"2005","journal-title":"J. Oral. Pathol. Med."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/j.1600-0714.2010.00946.x","article-title":"Pathogenesis of oral lichen planus--a review","volume":"39","author":"Roopashree","year":"2010","journal-title":"J. Oral Pathol. Med."},{"key":"ref_143","first-page":"1045","article-title":"Potential pathogenic mechanisms involved in the association between lichen planus and hepatitis C virus infection","volume":"17","author":"Georgescu","year":"2019","journal-title":"Exp. Med."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.clindermatol.2009.03.004","article-title":"Pathophysiology, etiologic factors, and clinical management of oral lichen planus, part I: Facts and controversies","volume":"28","author":"Farhi","year":"2010","journal-title":"Clin. Derm."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1046\/j.1365-2133.2001.04136.x","article-title":"Increased frequency of HLA-DR6 allele in Italian patients with hepatitis C virus-associated oral lichen planus","volume":"144","author":"Carrozzo","year":"2001","journal-title":"Br. J. Derm."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1034\/j.1601-0825.2001.00718.x","article-title":"Immunohistochemical study of oral lichen planus associated with hepatitis C virus infection, oral lichenoid contact sensitivity reaction and idiopathic oral lichen planus","volume":"7","author":"Mega","year":"2001","journal-title":"Oral Dis."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1034\/j.1601-0825.2002.10763.x","article-title":"Oral lichen planus and hepatitis C virus infection","volume":"8","author":"Figueiredo","year":"2002","journal-title":"Oral Dis."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1159\/000247552","article-title":"Lichen planus and virus C hepatitis: Disappearance of the lichen under interferon alfa therapy","volume":"184","author":"Doutre","year":"1992","journal-title":"Dermatology"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/0016-5085(93)91029-H","article-title":"Exacerbation of lichen planus during interferon alfa-2a therapy for chronic active hepatitis C","volume":"104","author":"Protzer","year":"1993","journal-title":"Gastroenterology"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S0190-9622(97)80296-4","article-title":"Oral erosive lichen planus with epidermolytic hyperkeratosis during interferon alfa-2b therapy for chronic hepatitis C virus infection","volume":"36","author":"Schlesinger","year":"1997","journal-title":"J. Am. Acad Derm."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"e179","DOI":"10.1038\/ctg.2016.37","article-title":"Successful Treatment of Hepatitis C Virus-associated Oral Lichen Planus by Interferon-free Therapy with Direct-acting Antivirals","volume":"7","author":"Nagao","year":"2016","journal-title":"Clin. Transl. Gastroenterol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1136\/annrheumdis-2014-205375","article-title":"Epidemiology of primary Sjogren\u2019s syndrome: A systematic review and meta-analysis","volume":"74","author":"Qin","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0889-857X(21)00317-3","article-title":"Salivary and oral components of Sjogren\u2019s syndrome","volume":"18","author":"Daniels","year":"1992","journal-title":"Rheum. Dis. Clin. North. Am."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/01.md.0000157397.30055.c9","article-title":"Sjogren syndrome associated with hepatitis C virus: A multicenter analysis of 137 cases","volume":"84","author":"Zeher","year":"2005","journal-title":"Medicine"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1186\/ar3361","article-title":"Immunopathologic differences of Sjogren\u2019s syndrome versus sicca syndrome in HCV and HIV infection","volume":"13","author":"Vitali","year":"2011","journal-title":"Arthritis Res."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2174\/1573397112666160714164149","article-title":"Update on Pathogenesis of Sjogren\u2019s Syndrome","volume":"13","author":"Sandhya","year":"2017","journal-title":"Curr. Rheumatol. Rev."},{"key":"ref_157","first-page":"2382","article-title":"Presence of hepatitis C virus RNA in the salivary glands of patients with Sjogren\u2019s syndrome and hepatitis C virus infection","volume":"29","author":"Toussirot","year":"2002","journal-title":"J. Rheumatol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.autrev.2004.04.004","article-title":"Hepatitis C virus, Sjogren\u2019s syndrome and B-cell lymphoma: Linking infection, autoimmunity and cancer","volume":"4","author":"Tzioufas","year":"2005","journal-title":"Autoimmun. Rev."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"S120","DOI":"10.1016\/j.jhep.2016.08.001","article-title":"Management of the patient with SVR","volume":"65","author":"Terrault","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1136\/ard.57.12.728","article-title":"Cryoglobulinaemia and rheumatic manifestations in patients with hepatitis C virus infection","volume":"57","author":"Lee","year":"1998","journal-title":"Ann. Rheum. Dis."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.semarthrit.2003.12.006","article-title":"The case for hepatitis C arthritis","volume":"33","author":"Rosner","year":"2004","journal-title":"Semin Arthritis Rheum."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.cld.2017.03.002","article-title":"Rheumatologic Manifestations of Hepatitis C Virus Infection","volume":"21","author":"Cacoub","year":"2017","journal-title":"Clin. Liver Dis."},{"key":"ref_163","first-page":"43","article-title":"Joint sonography in asymptomatic patients with HCV correlated hepatitis","volume":"22","author":"Iagnocco","year":"2004","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"573","DOI":"10.2165\/00063030-200115090-00002","article-title":"Management of hepatitis C virus-related arthritis","volume":"15","author":"Zuckerman","year":"2001","journal-title":"BioDrugs"},{"key":"ref_165","first-page":"489","article-title":"Absence of cyclic citrullinated peptide antibody in nonarthritic patients with chronic hepatitis C infection","volume":"32","author":"Lienesch","year":"2005","journal-title":"J. Rheumatol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"6550","DOI":"10.4049\/jimmunol.1102022","article-title":"Expansion of functionally anergic CD21-\/low marginal zone-like B cell clones in hepatitis C virus infection-related autoimmunity","volume":"187","author":"Terrier","year":"2011","journal-title":"J. Immunol."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.jbspin.2006.05.005","article-title":"Rheumatologic manifestations of chronic hepatitis C infection","volume":"73","author":"Lormeau","year":"2006","journal-title":"Jt. Bone Spine"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1517\/14656566.2014.946404","article-title":"An update on the management of hepatitis C virus-related arthritis","volume":"15","author":"Palazzi","year":"2014","journal-title":"Expert Opin Pharm."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"e021747","DOI":"10.1136\/bmjopen-2018-021747","article-title":"Risk of rheumatoid arthritis in patients with hepatitis C virus infection receiving interferon-based therapy: A retrospective cohort study using the Taiwanese national claims database","volume":"8","author":"Tung","year":"2018","journal-title":"BMJ Open"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"e239","DOI":"10.1097\/MEG.0000000000002015","article-title":"Direct antiviral drugs in the treatment of hepatitis C-infected rheumatoid arthritis Egyptian cohort: Safety and clinical impact","volume":"33","author":"Lashen","year":"2021","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/ncpendmet1027","article-title":"Endocrine manifestations of hepatitis C virus infection","volume":"5","author":"Antonelli","year":"2009","journal-title":"Nat. Clin. Pr. Endocrinol. Metab."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.amjmed.2004.01.023","article-title":"Thyroid disorders in chronic hepatitis C","volume":"117","author":"Antonelli","year":"2004","journal-title":"Am. J. Med."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1136\/gut.2005.076646","article-title":"Treating.g viral hepatitis C: Efficacy, side effects, and complications","volume":"55","author":"Manns","year":"2006","journal-title":"Gut"},{"key":"ref_174","first-page":"e18289","article-title":"Prevalence of Thyroid Dysfunction in Patients With Hepatitis C","volume":"13","author":"Nazary","year":"2021","journal-title":"Cureus"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/qjmed\/hch088","article-title":"Thyroid involvement in patients with overt HCV-related mixed cryoglobulinaemia","volume":"97","author":"Antonelli","year":"2004","journal-title":"QJM"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.autrev.2016.03.012","article-title":"Incidence of thyroid disorders in mixed cryoglobulinemia: Results from a longitudinal follow-up","volume":"15","author":"Fallahi","year":"2016","journal-title":"Autoimmun. Rev."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"J322","DOI":"10.1016\/j.jaut.2009.11.008","article-title":"Hepatitis C and interferon induced thyroiditis","volume":"34","author":"Tomer","year":"2010","journal-title":"J. Autoimmun."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1089\/thy.1997.7.421","article-title":"Failure to find an association between hepatitis C virus and thyroid autoimmunity","volume":"7","author":"Metcalfe","year":"1997","journal-title":"Thyroid"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"2390812","DOI":"10.1155\/2017\/2390812","article-title":"Thyroid Dysfunction in Non-Interferon Treated Hepatitis C Patients Residing in Hepatitis Endemic Area","volume":"2017","author":"Batool","year":"2017","journal-title":"Biomed. Res. Int"},{"key":"ref_180","doi-asserted-by":"crossref","unstructured":"Chang, Y.K., Tseng, Y.T., Chen, K.H., and Chen, K.T. (2019). Long-term outcomes and risk factors of thyroid dysfunction during pegylated interferon and ribavirin treatment in patients with chronic hepatitis C infection in Taiwan. BMC Endocr. Disord., 19.","DOI":"10.1186\/s12902-019-0362-7"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"83","DOI":"10.4254\/wjh.v8.i2.83","article-title":"Hepatitis C virus infection and thyroid autoimmune disorders: A model of interactions between the host and the environment","volume":"8","author":"Pastore","year":"2016","journal-title":"World J. Hepatol."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/jmv.21269","article-title":"Detection of hepatitis C virus in thyroid tissue from patients with chronic HCV infection","volume":"80","author":"Bartolome","year":"2008","journal-title":"J. Med. Virol."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1001\/archinte.158.13.1445","article-title":"Increased risk of autoimmune thyroid disease in hepatitis C vs hepatitis B before, during, and after discontinuing interferon therapy","volume":"158","author":"Gonzalez","year":"1998","journal-title":"Arch. Intern. Med."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"3868","DOI":"10.1002\/jmv.25931","article-title":"Comparing the risk of hypothyroidism in HCV patients treated with different DAA drugs combinations (sofosbuvir\u2009+\u2009interferon\u2009+\u2009ribavirin and sofosbuvir\u2009+\u2009daclatasvir\u2009+\u2009ribavirin)","volume":"92","author":"Wahid","year":"2020","journal-title":"J. Med. Virol."}],"container-title":["Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-7737\/12\/1\/23\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:48:29Z","timestamp":1760147309000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-7737\/12\/1\/23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,22]]},"references-count":184,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["biology12010023"],"URL":"https:\/\/doi.org\/10.3390\/biology12010023","relation":{},"ISSN":["2079-7737"],"issn-type":[{"value":"2079-7737","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,22]]}}}